Jump to content

Esmirtazapine: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
m clean up using AWB
BogBot (talk | contribs)
Bots
53,132 edits
populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot
Line 1: Line 1:
{{drugbox
{{Drugbox
⚫
| IUPAC_name = (''S'')-1,2,3,4,10,14b-hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine
⚫
| image = (S)-Mirtazapin Structural Formulae.png

<!--Clinical data-->
| tradename =
⚫
| pregnancy_category =
⚫
| legal_status = Uncontrolled
⚫
| routes_of_administration = [[Mouth|Oral]]

<!--Pharmacokinetic data-->
⚫
| bioavailability =
⚫
| metabolism = Liver ([[CYP2D6]])<ref name="urlwww.page-meeting.org">{{cite web | url = http://www.page-meeting.org/pdf_assets/2259-posterPAGE2008_SP.pdf | title = A population analysis on the effects of the CYP2D6 deficiency on pharmacokinetics and exposure of esmirtazapine in healthy volunteers}}</ref>
⚫
| elimination_half-life =
⚫
| excretion =

<!--Identifiers-->
⚫
| CAS_number = 61337-87-9
⚫
| ATC_prefix = none
⚫
| ATC_suffix =
⚫
| PubChem = 6451144
⚫
| ChemSpiderID = 4953625
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 4685R51V7M
| UNII = 4685R51V7M
⚫
| IUPAC_name = (''S'')-1,2,3,4,10,14b-hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine
⚫
| image = (S)-Mirtazapin Structural Formulae.png
⚫
| CAS_number = 61337-87-9
⚫
| ATC_prefix = none
⚫
| ATC_suffix =
⚫
| PubChem = 6451144
⚫
| ChemSpiderID = 4953625
| KEGG = D04055
| KEGG = D04055

| C = 21 | H = 23 | N = 3 | O = 4
<!--Chemical data-->
⚫
| molecular_weight = 381.43 g/mol
| melting_point = 114
| C=21 | H=23 | N=3 | O=4
⚫
| molecular_weight = 381.43 g/mol
⚫
| melting_high = 116
⚫
| smiles = CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4
⚫
| solubility = Soluble in [[methanol]] and [[chloroform]]
| melting_point = 114
⚫
| smiles = CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4
⚫
| melting_high = 116
⚫
| bioavailability =
⚫
| solubility = Soluble in [[methanol]] and [[chloroform]]
⚫
| metabolism = Liver ([[CYP2D6]])<ref name="urlwww.page-meeting.org">{{cite web | url = http://www.page-meeting.org/pdf_assets/2259-posterPAGE2008_SP.pdf | title = A population analysis on the effects of the CYP2D6 deficiency on pharmacokinetics and exposure of esmirtazapine in healthy volunteers}}</ref>
⚫
| elimination_half-life =
⚫
| excretion =
⚫
| pregnancy_category =
⚫
| legal_status = Uncontrolled
⚫
| routes_of_administration = [[Mouth|Oral]]
}}
}}


Revision as of 19:24, 20 September 2011

Esmirtazapine
Clinical data
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Pharmacokinetic data
MetabolismLiver (CYP2D6)[1]
Identifiers
  • (S)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.056.994 Edit this at Wikidata
Chemical and physical data
FormulaC21H23N3O4
Molar mass381.43 g/mol g·mol−1
3D model (JSmol)
Melting point114 to 116 °C (237 to 241 °F)
Solubility in waterSoluble in methanol and chloroform mg/mL (20 °C)
  • CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4

Esmirtazapine (ORG-50,081) is a drug which is under development by Organon for the treatment of insomnia and vasomotor symptoms (e.g., hot flashes) associated with menopause.[2][3][4][5] As of 2009 it is in phase III clinical trials.[2] Esmirtazapine is the (S)-(+)-enantiomer of mirtazapine and possesses similar overall pharmacology, including inverse agonist actions at H1 and 5-HT2 receptors and antagonist actions at α2-adrenergic receptors.[2][6] As of March 2010, Merck terminated internal clinical development program for esmirtazapine, for hot flashes and insomnia, for strategic reasons.[7]

See also

References

  1. ^ "A population analysis on the effects of the CYP2D6 deficiency on pharmacokinetics and exposure of esmirtazapine in healthy volunteers" (PDF).
  2. ^ a b c "Future Treatments for Depression, Anxiety, Sleep Disorders, Psychosis, and ADHD -- Neurotransmitter.net".
  3. ^ "A Long-Term Safety Study of Org 50081 in Elderly Outpatients With Chronic Primary Insomnia (176005)(P05697) - Full Text View - ClinicalTrials.gov".
  4. ^ Teegarden BR, Al Shamma H, Xiong Y (2008). "5-HT(2A) inverse-agonists for the treatment of insomnia". Current Topics in Medicinal Chemistry. 8 (11): 969–76. doi:10.2174/156802608784936700. PMID 18673166.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  5. ^ Lewis V (2009). "Undertreatment of menopausal symptoms and novel options for comprehensive management". Current Medical Research and Opinion. 25 (11): 2689–98. doi:10.1185/03007990903240519. PMID 19775194. {{cite journal}}: Unknown parameter |month= ignored (help)
  6. ^ Depression and bipolar disorder: Stahl's essential psychopharmacology. Cambridge, UK: Cambridge University Press. 2008. ISBN 0-521-88663-5.
  7. ^ http://www.merck.com/investors/financials/form-10-K-2009-final.pdf


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Stub icon

This article about an organic compound is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Esmirtazapine&oldid=451550851"